Cargando…
Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis
SUMMARY: Two comorbidity indices were adapted for use in the FREEDOM trial and significantly correlated with the number of medications and impaired health status at baseline. The indices have applications for the analysis of clinical trial data and would allow for the appropriate adjustment of comor...
Autores principales: | Silverman, S. L., Wang, A., Cheng, L., Yang, Y., Libanati, C., Geller, M., Grauer, A., Nevitt, M., Revicki, D., Viswanathan, H. N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715856/ https://www.ncbi.nlm.nih.gov/pubmed/26174879 http://dx.doi.org/10.1007/s00198-015-3215-x |
Ejemplares similares
-
Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension
por: Papapoulos, Socrates, et al.
Publicado: (2012) -
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015) -
The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
por: Bone, Henry G., et al.
Publicado: (2013) -
Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials
por: Siris, Ethel, et al.
Publicado: (2020) -
Determinants of imminent fracture risk in postmenopausal women with osteoporosis
por: Barron, R. L., et al.
Publicado: (2020)